The purpose of this study is to determine the activity of Glivec 400 mg po daily, as single
agent, in inducing a haematological response in Polycythemia Vera.
The patients will be asked to have additional bone marrow and blood samples collected: these
samples will be used to evaluate how the disease is responding to the drug.